The webinar will feature a presentation by Key Opinion Leader (KOL) Marwan Noel Sabbagh, M.D. (Cleveland Clinic). In conjunction with the Alzheimer’s Association International Conference (AAIC) taking place July 26-30, Cortexyme will present an update and baseline data from its Phase 2/3 GAIN Trial of atuzaginstat (COR388), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s disease, as well as introduce new evidence to support P. gingivalis, which has been found in the brain of Alzheimer’s patients, as an important upstream driver of Alzheimer’s disease pathology. During the webinar on July 30, Dr. Sabbagh will address Cortexyme abstracts presented at AAIC, in addition to discussing the current treatment landscape, recent activity in the field, and upstream approach to better address unmet medical need in treating patients with Alzheimer’s disease. Dr. Sabbagh and Cortexyme management will be available to answer questions following the formal presentations.

Cortexyme’s management team will also give an update on its ongoing GAIN Trial, a Phase 2/3 clinical trial of its lead small molecule, atuzaginstat, in Alzheimer’s disease, which is fully enrolled with topline data expected in Q4 2021. Atuzaginstat has been shown in previous Phase 1 studies to be well tolerated in both healthy subjects and in patients with Alzheimer’s disease.